Omnichannel engagement is now the expectation in pharma, blending digital and in-person interactions to meet HCPs where they are:
- Blending Channels: Successful strategies include following up in-person visits with personalized emails, scheduling video calls after webinars, and using SMS for timely reminders.
- Seamless Experience: Integration ensures HCPs receive consistent messaging and can engage with brands on their preferred channels and schedules.
- Data-Informed Outreach: Omnichannel platforms track engagement across all touchpoints, allowing marketers to refine strategies and personalize outreach based on real-time data.
- Compliance and Consistency: Coordinated messaging across channels reduces the risk of non-compliance and message fragmentation, which is critical in regulated environments.
Example: After launching a new cardiovascular drug, a pharma company used an omnichannel platform to coordinate rep visits, digital detailing, and educational webinars. HCPs who engaged across multiple channels showed 30% higher prescribing rates than those reached through a single channel.
Best Practices for Synchronization
How Leading Pharma Companies Achieve Alignment
To achieve and sustain alignment, leading pharma companies are adopting the following best practices:
- Unified HCP Lists: This ensures that all relevant HCPs are included in both field and digital campaigns, eliminating gaps in coverage.
- Personalized Engagement: Tailoring content and channel mix to HCP preferences and behaviors, supported by robust segmentation and analytics.
- Integrated Data: Using unified CRM and marketing automation platforms to provide a single, actionable view of the customer for both sales and marketing teams.
- Clear Rules of Engagement: Establishing segment-specific strategies and measurable performance metrics to guide field and marketing activities.
- Cross-Functional Collaboration: Involving sales, marketing, analytics, and compliance teams from the outset to ensure buy-in and effective execution.
- Continuous Training: Providing ongoing training and development to keep teams aligned with the latest strategies, tools, and best practices.
Example: A mid-sized pharma company created a cross-functional “customer engagement council” with representatives from sales, marketing, analytics, and compliance. This group met monthly to review segmentation results, campaign performance, and field feedback, enabling rapid adjustment of strategies and fostering a culture of collaboration.
Implementation and Organizational Change
Making Segmentation and Synchronization Stick
Implementing advanced segmentation and synchronization strategies requires more than analytics demands cultural and operational change:
- Organizational Buy-In: Success depends on leadership commitment and cross-functional support for segmentation and alignment initiatives.
- Training and Systems: Teams must be trained on new segmentation results and business information systems updated to support differential messaging and targeting by segment.
- Performance Tracking: Organizations should monitor execution against new segments, track ROI at the segment level, and adapt strategies based on real-world feedback and results.
- Iterative Improvement: Formal evaluations, pilot programs, and messaging tracking studies help refine segmentation and alignment strategies, ensuring continuous improvement and learning.
Example: A global pharma company piloted a new segmentation-driven targeting approach in two regions. They tracked ROI, message recall, and HCP satisfaction, using the results to refine their approach before rolling it out nationally. This iterative process led to a 12% increase in promotional ROI and higher rep satisfaction.
A Modern Segmentation Framework: Steps and Criteria
Key Steps for Best-in-Class Segmentation
- Organizational Support: Secure leadership commitment and cross-functional involvement from sales, marketing, analytics, and IT.
- Define Segmentation Variables: Integrate behavioral, demographic, attitudinal, and geographic data to capture a holistic view of HCPs and institutions.
- Choose Methodology: Use a mix of a priori (business-driven) and post hoc (data-driven) approaches, leveraging both supervised and unsupervised analytics as appropriate.
- Data Quality and Integration: Ensure data sources are accurate, up-to-date, and granular, integrating CRM, sales, and market research inputs.
- Execution: Roll out segmentation results to all customer-facing teams, update CRM and sales force automation systems, and provide targeted training.
- Performance Measurement: Track execution at the segment level, measure ROI, and adjust strategies based on real-world results.
Example: A pharma company used prescribing behavior, digital engagement, and attitudinal data to segment its HCP base. They developed segment-specific content and adjusted sales force deployment accordingly.
Quarterly reviews ensured segments remained stable and actionable, with ongoing refinement as new data became available.
Lessons from Implementation: Common Pitfalls and Solutions
Common Challenges
- Siloed Data and Teams: Sales and marketing often operate in silos, leading to inconsistent segmentation and missed opportunities.
- Over-Reliance on Historical Metrics: Focusing only on past revenue or prescribing volume ignores future potential and strategic fit.
- Failure to Execute: Even the best segmentation is useless if not translated into frontline action with clear rules of engagement.
Solutions
- Integrated Platforms: Use unified CRM and marketing automation systems to break down silos and provide a single source of truth.
- Forward-Looking Metrics: Incorporate growth potential, innovation adoption, and network influence into segmentation criteria.
- Clear Rules and Training: Develop segment-specific engagement plans and train all customer-facing teams on their execution.
Conclusion: The Path Forward
In 2025, synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies seeking growth and competitive advantage. By adopting advanced segmentation, leveraging integrated technology platforms, and embracing omnichannel engagement, organizations can maximize promotional ROI, build stronger HCP relationships, and achieve sustainable success in an increasingly complex market.
Illustrative Case Study:
A global top-10 pharmaceutical company faced declining ROI from its traditional sales model. By moving to an integrated, customer-based segmentation process:
- They combined real-world prescribing data, digital engagement metrics, and attitudinal insights.
- Sales and marketing jointly developed HCP segments, including “Digital Early Adopters,” “Clinical Skeptics,” and “Network Influencers.”
- Omnichannel campaigns were tailored to each segment, with coordinated rep visits, webinars, and digital content.
- CRM and AI tools provided real-time feedback, allowing rapid adjustment of tactics.
Results:
- 18% increase in new product adoption among “Digital Early Adopters.”
- 25% reduction in marketing spend per incremental prescription.
- Improved HCP satisfaction and more substantial brand equity.
By embracing these strategies, pharmaceutical companies can thrive in today’s complex environment, turning alignment into a powerful driver of commercial success.
About the Authors
Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited, a $1.7B multinational digital solutions and technology consulting services company. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He was a member of the IBM Industry Academy, a highly selective group of professionals inducted by invitation only, the highest honor at IBM. He is a healthcare expert member of the World Economic Forum (WEF). He is also a Life Sciences industry advisor at MIT, his alma mater.
Wei Zhang is a Kingland Faculty Fellow in Business Analytics and Associate Professor of Marketing at the Debbie and Jerry Ivy College of Business, Iowa State University. He is also the founding director of the Ivy Business Analytics & Digital Strategy Forum. Before joining Iowa State University, he spent nearly a decade in industry. After earning his Ph.D. from Carnegie Mellon University, he joined McKinsey & Company as a management consultant. Subsequently, he held various managerial positions in pharmaceutical companies, including Amgen, Bristol-Myers Squibb, and Altus Pharmaceuticals, before ultimately becoming the co-founder and COO of Effigene Pharmaceuticals, an Atlanta-based company. His research has appeared in the Journal of Marketing Research, Marketing Science, Management Science, Journal of Consumer Research, and Nature Communications.